Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Coates, LC, FitzGerald, O, Merola, JF, Smolen, J, van Mens, LJJ, Bertheussen, H, Boehncke, W-H, Callis Duffin, K, Campbell, W, de Wit, M, Gladman, D, Gottlieb, A, James, J, Kavanaugh, A, Kristensen, LE, Kvien, TK, Luger, T, McHugh, N, Mease, P, Nash, P, Ogdie, A, Rosen, CF, Strand, V, Tillett, W, Veale, DJ & Helliwell, PS 2018, 'Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis' Arthritis & rheumatology (Hoboken, N.J.), vol. 70, no. 3, pp. 345-355. https://doi.org/10.1002/art.40391

APA

CBE

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke W-H, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS. 2018. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.). 70(3):345-355. https://doi.org/10.1002/art.40391

MLA

Vancouver

Author

Coates, Laura C ; FitzGerald, Oliver ; Merola, Joseph F ; Smolen, Josef ; van Mens, Leonieke J J ; Bertheussen, Heidi ; Boehncke, Wolf-Henning ; Callis Duffin, Kristina ; Campbell, Willemina ; de Wit, Maarten ; Gladman, Dafna ; Gottlieb, Alice ; James, Jana ; Kavanaugh, Arthur ; Kristensen, Lars Erik ; Kvien, Tore K ; Luger, Thomas ; McHugh, Neil ; Mease, Philip ; Nash, Peter ; Ogdie, Alexis ; Rosen, Cheryl F ; Strand, Vibeke ; Tillett, William ; Veale, Douglas J ; Helliwell, Philip S. / Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. In: Arthritis & rheumatology (Hoboken, N.J.). 2018 ; Vol. 70, No. 3. pp. 345-355.

Bibtex

@article{530713d988b34f709102ae60164ffa01,
title = "Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis",
abstract = "OBJECTIVE: A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).METHODS: Prior to the meeting, physicians and patients completed surveys on outcome measures. A consensus meeting of 26 rheumatologists, dermatologists, and patient research partners reviewed evidence on composite measures and potential treatment targets plus results of the surveys. The meeting consisted of plenary presentations, breakout sessions, and group discussions. International experts including members of GRAPPA and OMERACT were invited to the meeting, including the developers of all of the measures discussed. After discussions, participants voted on proposals for use, and consensus was established in a second survey.RESULTS: Survey results from 128 health care professionals and 139 patients were analyzed alongside a systematic literature review summarizing evidence. A weighted vote was cast for composite measures. For randomized controlled trials, the most popular measures were the PsA disease activity score (40 votes) and the GRAPPA composite index (28 votes). For clinical practice, the most popular measures were an average of scores on 3 visual analog scales (45 votes) and the disease activity in PsA score (26 votes). After discussion, there was no consensus on a composite measure. The group agreed that several composite measures could be used and that future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target, with minimal disease activity (MDA)/low disease activity as a feasible alternative. The target should include assessment of musculoskeletal disease, skin disease, and health-related quality of life. The group recommended a treatment target of very low disease activity (VLDA) or MDA.CONCLUSION: Consensus was not reached on a continuous measure of disease activity. In the interim, the group recommended several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies.",
keywords = "Journal Article",
author = "Coates, {Laura C} and Oliver FitzGerald and Merola, {Joseph F} and Josef Smolen and {van Mens}, {Leonieke J J} and Heidi Bertheussen and Wolf-Henning Boehncke and {Callis Duffin}, Kristina and Willemina Campbell and {de Wit}, Maarten and Dafna Gladman and Alice Gottlieb and Jana James and Arthur Kavanaugh and Kristensen, {Lars Erik} and Kvien, {Tore K} and Thomas Luger and Neil McHugh and Philip Mease and Peter Nash and Alexis Ogdie and Rosen, {Cheryl F} and Vibeke Strand and William Tillett and Veale, {Douglas J} and Helliwell, {Philip S}",
note = "{\circledC} 2017, American College of Rheumatology.",
year = "2018",
month = "3",
doi = "10.1002/art.40391",
language = "English",
volume = "70",
pages = "345--355",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis

AU - Coates, Laura C

AU - FitzGerald, Oliver

AU - Merola, Joseph F

AU - Smolen, Josef

AU - van Mens, Leonieke J J

AU - Bertheussen, Heidi

AU - Boehncke, Wolf-Henning

AU - Callis Duffin, Kristina

AU - Campbell, Willemina

AU - de Wit, Maarten

AU - Gladman, Dafna

AU - Gottlieb, Alice

AU - James, Jana

AU - Kavanaugh, Arthur

AU - Kristensen, Lars Erik

AU - Kvien, Tore K

AU - Luger, Thomas

AU - McHugh, Neil

AU - Mease, Philip

AU - Nash, Peter

AU - Ogdie, Alexis

AU - Rosen, Cheryl F

AU - Strand, Vibeke

AU - Tillett, William

AU - Veale, Douglas J

AU - Helliwell, Philip S

N1 - © 2017, American College of Rheumatology.

PY - 2018/3

Y1 - 2018/3

N2 - OBJECTIVE: A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).METHODS: Prior to the meeting, physicians and patients completed surveys on outcome measures. A consensus meeting of 26 rheumatologists, dermatologists, and patient research partners reviewed evidence on composite measures and potential treatment targets plus results of the surveys. The meeting consisted of plenary presentations, breakout sessions, and group discussions. International experts including members of GRAPPA and OMERACT were invited to the meeting, including the developers of all of the measures discussed. After discussions, participants voted on proposals for use, and consensus was established in a second survey.RESULTS: Survey results from 128 health care professionals and 139 patients were analyzed alongside a systematic literature review summarizing evidence. A weighted vote was cast for composite measures. For randomized controlled trials, the most popular measures were the PsA disease activity score (40 votes) and the GRAPPA composite index (28 votes). For clinical practice, the most popular measures were an average of scores on 3 visual analog scales (45 votes) and the disease activity in PsA score (26 votes). After discussion, there was no consensus on a composite measure. The group agreed that several composite measures could be used and that future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target, with minimal disease activity (MDA)/low disease activity as a feasible alternative. The target should include assessment of musculoskeletal disease, skin disease, and health-related quality of life. The group recommended a treatment target of very low disease activity (VLDA) or MDA.CONCLUSION: Consensus was not reached on a continuous measure of disease activity. In the interim, the group recommended several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies.

AB - OBJECTIVE: A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).METHODS: Prior to the meeting, physicians and patients completed surveys on outcome measures. A consensus meeting of 26 rheumatologists, dermatologists, and patient research partners reviewed evidence on composite measures and potential treatment targets plus results of the surveys. The meeting consisted of plenary presentations, breakout sessions, and group discussions. International experts including members of GRAPPA and OMERACT were invited to the meeting, including the developers of all of the measures discussed. After discussions, participants voted on proposals for use, and consensus was established in a second survey.RESULTS: Survey results from 128 health care professionals and 139 patients were analyzed alongside a systematic literature review summarizing evidence. A weighted vote was cast for composite measures. For randomized controlled trials, the most popular measures were the PsA disease activity score (40 votes) and the GRAPPA composite index (28 votes). For clinical practice, the most popular measures were an average of scores on 3 visual analog scales (45 votes) and the disease activity in PsA score (26 votes). After discussion, there was no consensus on a composite measure. The group agreed that several composite measures could be used and that future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target, with minimal disease activity (MDA)/low disease activity as a feasible alternative. The target should include assessment of musculoskeletal disease, skin disease, and health-related quality of life. The group recommended a treatment target of very low disease activity (VLDA) or MDA.CONCLUSION: Consensus was not reached on a continuous measure of disease activity. In the interim, the group recommended several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies.

KW - Journal Article

U2 - 10.1002/art.40391

DO - 10.1002/art.40391

M3 - Journal article

VL - 70

SP - 345

EP - 355

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -

ID: 53652787